Cumberland Pharmaceuticals Inc. Q2 FY2025 earnings call

• Vibativ received approval from Chinese regulatory authorities, providing access to the world's second largest pharmaceutical market, and preparations for its launch in China and partnership with Tabuk Pharmaceuticals for the Middle East are underway.
• Kristalose, a prescription strength laxative, is being enhanced with updated marketing materials and new specialty distribution partnerships.
• Caldolor, an intravenous ibuprofen product, has a new pediatric labeling cleared by the FDA, and a study on its safety and efficacy for postoperative pain in patients 60+ was published.
• Sancuso, an FDA-approved transdermal patch for chemotherapy-induced nausea, has favorable sales results following expansion of the oncology sales force and new patient support services.
• Ifetroban product candidate showed positive results in Phase II study for Duchenne muscular dystrophy, with ongoing clinical trials in systemic sclerosis and idiopathic pulmonary fibrosis; partnership with Qureight to enhance data from the idiopathic pulmonary fibrosis trial.

For the second quarter of 2025, the portfolio of FDA-approved brands delivered combined revenues of $10.8 million, a 10% increase over the same period last year. Year-to-date revenues for the first 6 months of 2025 totaled $22.6 million, a 23% increase over the prior year period. Adjusted earnings for the second quarter were $0.4 million, and for the first half of 2025, adjusted earnings were $2.8 million or $0.18 a share. Cash flow from operations during the first 6 months of 2025 was $4.7 million. Net revenue by product for the second quarter of 2025: Kristalose was $2.8 million, Sancuso was $3.1 million, Vibativ was $2.7 million, and Caldolor was $1.6 million. Year-to-date, product revenue was $6.2 million for Kristalose, $4.1 million for Vibativ, $5.4 million for Sancuso, and $2.9 million for Caldolor.

• Expect continued momentum across approved brands.
• Anticipate increased international contributions.
• Look for further progress in clinical pipeline.
• New opportunities through select addition of new products.

• Factors affecting future results include natural disasters, economic downturns, public health epidemics, international conflicts, trade restrictions, etc., as described in Cumberland's Form 10-K and additional SEC filings.

Q: A: Q: A: